ÇÐȸ¼Ò½Ä
±¸ºÐ | Çмú»ó¸í | ¸í¼ö | ¼ö»óÀÚ | ¼Ò¼Ó | ÁÖ Á¦ | Çмú»ó±Ý | ||
1 | ¸í¹ÎÇмú»ó ÃÖ¿ì¼ö³í¹®»ó |
1¸í | Á¦1ÀúÀÚ : ±ÇÅÃÁÖ Ã¥ÀÓÀúÀÚ : Á¤ÁøÇâ |
°æºÏÀÇ´ë | °©»ó¼± À¯µÎ¾ÏÀÇ ¿¹ÈÄ ¿¹Ãø ÀÎÀڷμ BRAF V600E µ¹¿¬º¯ÀÌÀÇ ¿ªÇÒ | °¢ 50¸¸¿ø | ||
2 | ¸í¹ÎÇмú»ó ÃÖ´Ù³í¹®»ó |
1¸í | Á¦1ÀúÀÚ : ³ª¾È¼ö Ã¥ÀÓÀúÀÚ : À±ÇöÁ¶ |
ÀüºÏÀÇ´ë | °©»ó¼± ÀüÀýÁ¦¼ú ÈÄ ÀúÄ®½·Ç÷ÁõÀ» ¿¹ÃøÇϱâ À§ÇÑ ºÎ°©»ó¼± È£¸£¸ó ¼öÄ¡ | °¢ 50¸¸¿ø | ||
3 | ¸í¹ÎÇмú»ó ³í¹®Åõ°í»ó |
4¸í | Á¦1ÀúÀÚ : ¿ÀÀº¹Ì Ã¥ÀÓÀúÀÚ : ÀÌ¿µµ· |
°¡ÃµÀÇ´ë | °©»ó¼± ÀüÀýÁ¦¼ú ÈÄ ¹ß»ýÇÑ ÀÏ°ú¼º ºÎ°©»ó¼±±â´ÉÀúÇÏÁõ ȯÀÚ ±º¿¡¼ Á¶±â ȸº¹ ±ºÀÇ ÀÓ»ó Ư¡ |
°¢ 50¸¸¿ø | ||
Comparative Analysis of Three Lobectomy Methods for Papillary Thyroid Cancer |
||||||||
Á¦1ÀúÀÚ : ¼¼öÇÑ Ã¥ÀÓÀúÀÚ : ¼ÒÀÇ¿µ |
Æ÷Ç×¼º¸ðº´¿ø | °©»ó¼±¾Ï ȯÀÚ¿¡¼ Ãø°æºÎ ¸²ÇÃÀý ÀüÀÌ¿©ºÎ Áø´Ü¿¡ ¼¼Ä§ÈíÀÔ¼¼Æ÷ °Ë»ç°¡ ¹ÏÀ»¸¸ÇÑ°¡? |
||||||
Á¦1ÀúÀÚ : °¼ºÀÌ Ã¥ÀÓÀúÀÚ : ±èµ¿ÁÖ |
ÃæºÏÀÇ´ë | µ¿¹ÝµÈ ¾ç¼º °©»ó¼± Áúȯ¿¡ µû¸¥ °©»ó¼± À¯µÎ¾ÏÀÇ ÀÓ»óº´¸®ÇÐÀû Ư¼º | ||||||
Á¦1ÀúÀÚ : ±èö¼ö Ã¥ÀÓÀúÀÚ : ±Ç¼ö°æ |
°í½ÅÀÇ´ë | ¼ö¼úÈÄ ºÎ°©»ó¼±¼±±â´ÉÀúÇÏÁõ ȯÀÚ¿¡¼ ¹ß»ýÇÑ ¿ìÀ¯-¾ËÄ®¸® ÁõÈıº | ||||||
4 | KABTS ¿ì¼ö¿¬Á¦¹ßÇ¥»ó |
4¸í | ¼Çö¼® | ¼¿ïÀÇ´ë | Elastic scattering for discrimination of benign from mailgnant disease in thyroid nodules |
°¢ 50¸¸¿ø | ||
±è¼±â | ¼º±Õ°üÀÇ´ë | Prediction table and nomogram as tools for diagnosis of papillary thyroid carcinoma: combined analysis of ultrasonography, fine needle aspiration biopsy, and BRAF V600E mutation |
||||||
±èÇü±Ô | ¿¬¼¼ÀÇ´ë | The incidence of cancer in thyroid nodules 4cm or larger with preoperative FNAB benign cytology. |
||||||
Á¶Áø¼º | Àü³²ÀÇ´ë | Radioactive iodine therapy can be omitted in some intermediate risk N1a Papillary throid cancer patients - Especially on less than 50% of positive node ratio |
||||||
5 | Çѹ̿ì¼öÆ÷½ºÅÍ»ó | 2¸í | ¼¿ëÁØ | ¼¿ïÀÇ´ë | Application of immunohistochemistry markers to classify thyroid neoplasm | °¢ 50¸¸¿ø | ||
±è¿ì¿µ | °í·ÁÀÇ´ë | Endoplasmic reticulum aminopeptidase 2 (ERAP2) is highly expressed in papillary microcarcinoma with cervical lymph node metastasis |
||||||